Mangalam Drugs And Organics (MANGALAM) is loss-making over the last 12 months, losing ₹38 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹28.80, 55% below its 52-week high. Sales fell 14% a year over 3 years. Debt is 1.09× equity. It is a small-cap company with a market cap of ₹46 Cr, ranked 132nd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 53% over the past year.
- ₹30.64
- ₹30.88
- ₹27.58
- ₹30.64
- 48.3K
Health check
- ReturnsBehind
−53.5% over a year, better than 0 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthShrinking
Sales −14.3% a year over 3 years.
- ProfitabilityNegative
ROCE -30.7% vs peer median 17.9%.
- Balance sheetStretched
Debt 1.09× equity, operating profit doesn’t cover interest.
- Red flags5 to check
Loss-making over the last twelve months.
Small cap
Defensive
Key metrics
- Market cap
- ₹46 Cr
- Small cap
- P/E
- n/a
- Industry 28.7
- Price to book
- 0.44
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- −35.2%
- Peers 14.7%
- ROCE
- −30.7%
- Peers 17.9%
- Debt to equity
- 1.09
- Debt ₹113 Cr
- EPS (TTM)
- −₹24.16
- Face value ₹10
- OPM (TTM)
- −3.9%
- Net margin −16.5%
- Sales growth
- −0.2%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 0.20
- EV/EBITDA −22.3
Strengths and risks
Strengths
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −35.2%.
- Quarterly sales down 0.2% on a year ago.
- 55% below its 52-week high.
- Interest coverage of only −1.1×.
About Mangalam Drugs And Organics
Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine,…
- Headquarters
- Mumbai
- Employees
- 319
- Sector
- Healthcare
- ISIN
- INE584F01014
- Website
- mangalamdrugs.com
Price range
- Avg volume (3M)
- 54.3K
- 1-year return
- minus 53.5%
- From 52-week high
- minus 55.3%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| MANGALAMMangalam Drugs And Organics | 28.80 | minus 6.01% | 46 | – | 0.44 | – | −37.1% | −5.4% | – | – | 0.00% | minus 53.5% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 57.2 | 49.3 | 58.4 | 67.3 | 57.1 | |
| 61.8 | 52.1 | 59.8 | 72.9 | 56.2 | |
| −4.6 | −2.8 | −1.4 | −5.6 | 0.9 | |
| −8.1% | −5.8% | −2.5% | −8.4% | 1.6% | |
| 0.1 | 0 | 0.1 | 0.1 | 0.1 | |
| 4 | 5 | 4.1 | 3.1 | 3.7 | |
| 4.5 | 4.6 | 4.5 | 4.7 | 4.1 | |
| −13 | −12.5 | −9.8 | −13.3 | −6.7 | |
| −6.2% | 41.1% | 0.0% | −1.1% | −13.2% | |
| −13.8 | −7.3 | −9.8 | −13.4 | −7.6 | |
| -8.72 | -4.64 | -6.21 | -8.48 | -4.83 |
Profit & loss
- Sales CAGR 3Y
- −14.3%
- ROE
- −35.2%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 366 | 365 | 315 | 230 | |
| – | minus 0.1% | minus 13.8% | minus 26.9% | |
| 340 | 357 | 282 | 244 | |
| 25.6 | 8.5 | 33.4 | −14.1 | |
| 7.0% | 2.3% | 10.6% | −6.1% | |
| −3.4 | −1.7 | −0.9 | −1.6 | |
| 8.9 | 10.4 | 11.2 | 12.3 | |
| 11 | 7.5 | 16.6 | 18.2 | |
| −0 | −0.1 | 0.1 | −2.3 | |
| 2.2 | −11.1 | 4.8 | −48.6 | |
| 42.6% | 18.1% | −40.4% | 8.6% | |
| 1.3 | −9.1 | 6.7 | −44.4 | |
| – | minus 814.3% | – | minus 760.6% | |
| 0.80 | -5.73 | 4.25 | -28.05 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 15.8 | 15.8 | 15.8 | 15.8 | |
| 136 | 120 | 133 | 87.2 | |
| 88.5 | 106 | 96.2 | 113 | |
| 119 | 92.3 | 121 | 99.2 | |
| 360 | 334 | 366 | 315 | |
| 134 | 129 | 137 | 126 | |
| 7.3 | 2.2 | 3.3 | 0.3 | |
| 0 | 0 | 0 | 0 | |
| 2.7 | 1.2 | 2.6 | 0.7 | |
| 215 | 201 | 224 | 188 | |
| 360 | 334 | 366 | 315 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 39.5 | 3.9 | 42.6 | 4.2 | |
| −22.2 | −11.8 | −19.5 | −11.7 | |
| −16.6 | 5.2 | −21.7 | 5.7 | |
| 0.7 | −2.7 | 1.4 | −1.9 | |
| −27.9 | −11.8 | −20.2 | −11.9 | |
| 11.6 | −7.9 | 22.4 | −7.7 |
Shareholding pattern
- Promoters35.65%
- Public64.35%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 35.65% | 64.35% | 0.00 | |
| 30 Jun 2026 | 35.65% | 64.35% | 0.00 | |
| 31 Mar 2026 | 35.65% | 64.35% | plus 0.01 | |
| 31 Dec 2025 | 35.64% | 64.36% | minus 14.66 | |
| 30 Sep 2025 | 50.30% | 49.70% | – |
Major shareholders
Filings & events
News
No recent news coverage found.